Patent US6007774A successfully refreshed from Google Patents.
US6007774A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the treatment of organ ischemia or infarct comprising hemodilution
Assignee: PFC Therapeutics LLC
•
Filing: 1998-06-18
•
Granted: 1999-12-28
•
Expires: 2018-06-18
Abstract
Abstract A method for treating conditions associated with ischemia or infarct is disclosed which includes the steps of administering a biocompatible non-blood oxygen carrier while monitoring one or more oxygenation indices to maintain oxygenation of the patient's tissues at or above a predetermined level.
Inventors
- 👤 Nicholas Simon Faithfull
- 👤 Peter E. Keipert
- 👤 Duane J. Roth
- 👤 Ronald M. Hopkins
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 06:42
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/41; A61K38/42; A61K31/00; A61K31/02; A61K31/025; A61K33/00; A61P; A61P7/00; A61P7/08
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
92 words
A method for the treatment of organ ischemia or infarct, comprising the steps of: removing a portion of the blood of a patient in need of treatment for organ ischemia or infarct and intravenously administering a biocompatible liquid in sufficient quantity to reduce the patient's blood hemoglobin level to a desired concentration; monitoring one or more tissue oxygenation indices to assess the patient's tissue oxygenation; and intravenously administering a biocompatible non-blood oxygen carrier in response to the oxygen assessments to maintain oxygenation of the patient's tissues at or above a predetermined level.
Claim 2
Independent Claim
92 words
A method for the treatment of organ ischemia or infarct, comprising the steps of: removing a portion of the blood of a patient in need of treatment for organ ischemia or infarct and intravenously administering a biocompatible liquid in sufficient quantity to reduce the patient's blood hemoglobin level to a desired concentration; monitoring one or more tissue oxygenation indices to assess the patient's tissue oxygenation; and intravenously administering a biocompatible non-blood oxygen carrier in response to the oxygen assessments to maintain oxygenation of the patient's tissues at or above a predetermined level.
Claim 3
Dependent Claim
12 words
The method of claim 1, wherein the biocompatible liquid comprises a hemodiluent.
Claim 4
Dependent Claim
15 words
The method of claim 2, wherein said hemodiluent is administered separately from said oxygen carrier.
Claim 5
Dependent Claim
18 words
The method of claim 1, wherein the oxygen carrier is derived from human, animal, plant, or recombinant hemoglobin.
Claim 6
Dependent Claim
33 words
The method of claim 1, wherein the said oxygen carrier is a fluorocarbon emulsion and the volume of said administered oxygen carrier is less than 50% of the volume of said biocompatible liquid.
Claim 7
Dependent Claim
13 words
The method of claim 1, wherein the oxygen carrier is a fluorocarbon emulsion.
Claim 8
Dependent Claim
17 words
The method of claim 6, wherein said fluorocarbon emulsion has a concentration of at least 40%, w/v.
Claim 9
Dependent Claim
17 words
The method of claim 6, wherein the concentration of said fluorocarbon emulsion is at least 60%, w/v.
Claim 10
Dependent Claim
27 words
The method of claim 1, wherein said biocompatible liquid is selected from the group consisting of crystalloid plasma volume expanders, colloid plasma volume expanders and combinations thereof.
Claim 11
Dependent Claim
17 words
The method of claim 1, further comprising the step of administering oxygen breathing gas to the patient.
Claim 12
Dependent Claim
27 words
The method of claim 1, wherein the amount of oxygen carrier administered is between about 0.5 and 10 ml/kg, based on the body weight of the patient.
Claim 13
Dependent Claim
15 words
The method of claim 1, wherein said desired concentration of hemoglobin is about 8 g/dL.
Claim 14
Dependent Claim
16 words
The method of claim 1, wherein monitoring the patient's oxygen indices comprises measuring PvO 2 .
Claim 15
Dependent Claim
17 words
The method of claim 13 wherein a predetermined value of said PvO2 is about 40 mm Hg.
Claim 16
Dependent Claim
16 words
The method of claim 1, wherein the oxygen carrier and the biocompatible liquid are administered simultaneously.
Claim 17
Dependent Claim
12 words
The method of claim 1, wherein said infarct is a myocardial infarct.
References Cited (Backward Citations)
US3975512A
Cited
US4073879A
Cited
US4301144A
Cited
US4777244A
Cited
US4473494A
Cited
US4698387A
Cited
US4526715A
Cited
US4600531A
Cited
EP0231070A2
Cited
US4987154A
Cited
US4911929A
Cited
US4857636A
Cited
US4861867A
Cited
US5344393A
Cited
US5451205A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-12-27 | 2003-06-28 | 2003-12-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-12-27 | 2007-06-28 | 2007-12-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-12-27 | 2011-06-28 | 2011-12-28 | $7700.00 | Window Closed / Lapsed |